Search clinical trials for: Insulin glargine (LANTUS)

Total 3239 results

AstraZeneca

Completed

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

Type 2 Diabetes Mellitus

United States, Poland, Mexico, Hungary, Spain, Romania, South Africa, Denmark, Czechia, Sweden
São Paulo State University

Completed

The Prebiotic Effect of Daily Intake of Orange Juice Affects the Bioavailability of Flavanones?

Intestinal Diseases

Brazil
GlaxoSmithKline

Completed

A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Russian Federation, United Kingdom, South Africa
Eli Lilly and Company

Completed

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Sanofi

Terminated

Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care (RELIANCE)

Diabetes Mellitus, Type 2

Australia
Eli Lilly and Company
Alkermes, Inc.

Completed

Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany, Puerto Rico, United Kingdom, Spain, Canada, Brazil, Korea, Republic of, India, Israel, Russian Federation, South Africa
Karolinska Institutet

Unknown

Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis (BAS)

Diabetes Mellitus Type 1

Sweden
Yale University

Completed

Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin

Type 1 Diabetes Mellitus

United States
Mannkind Corporation

Terminated

Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler

Type 2 Diabetes

United States
Eli Lilly and Company
Cipla Ltd.

Recruiting

A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India

Diabetes Mellitus, Type 2

India
Xijing Hospital

Unknown

A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use

Type 2 Diabetes Mellitus

China
Eli Lilly and Company

Completed

Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Puerto Rico
Imperial College London

Completed

Human Urinary Biomarker for Orange Juice Consumption

Healthy

United Kingdom
Sanofi

Completed

Opposing Step-by-step Insulin Reinforcement to Intensified Strategy (OSIRIS)

Diabetes Mellitus, Type 2

France, Korea, Republic of, Russian Federation, Spain, Italy, Belgium, Germany, Hungary, Ireland, Mexico, Poland, Taiwan, Turkey, Netherlands, Greece, Lithuania, Sweden, United Kingdom
Eli Lilly and Company

Completed

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)

Diabetes Mellitus, Type 2

Canada, Hungary, Spain, United States, Australia, Puerto Rico, Poland, Belgium, Denmark, Brazil, Mexico, Greece, Argentina, Taiwan, Sweden, Russian Federation
King Edward Medical University

Completed

Comparison of Insulin Glargine and Regular Insulin Versus NPH and Regular Insulin in the Treatment of T1DM

To Assess the Glycemic Control of Insulin Glargine in Combination With Regular Insulin in Type 1 Diabetes in Children

Pakistan
Eli Lilly and Company

Active, not recruiting

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) (QWINT-1)

Type 2 Diabetes | T2D

United States, Mexico, Argentina, Puerto Rico
Second Affiliated Hospital, School of Medicine,...

Recruiting

Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM

Time in Range | HbA1c | Type 1 Diabetes Mellitus With Diabetic Gastroparesis

China
Eli Lilly and Company

Completed

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes

Type 1 Diabetes Mellitus

China, Argentina, Mexico
Eli Lilly and Company

Completed

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes

Type 2 Diabetes Mellitus

China, Mexico, Argentina
Jing Luo
The Leona M. and Harry B. Helmsley Charitable Trust

Active, not recruiting

Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings (HumAn-1)

Diabetes Mellitus, Type 1 | Type 1 Diabetes

Tanzania, Bangladesh
Eli Lilly and Company

Completed

A Study of LY3192767 in Healthy Participants

Healthy

Germany
Eli Lilly and Company

Completed

A Study of LY900014 in Participants With Type 1 Diabetes (PRONTO-T1D)

Type 1 Diabetes Mellitus

Italy, Japan, United States, Puerto Rico, Spain, Taiwan, Mexico, Austria, Germany, Poland, New Zealand, Romania, Russian Federation, Argentina, India, Sweden, Slovakia, Australia, Brazil, Greece
Eli Lilly and Company

Completed

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes (PRONTO-Peds)

Type 1 Diabetes Mellitus

United States, Czechia, France, Spain, Japan, Germany, Italy, Brazil, Denmark, Austria, United Kingdom, China, Russian Federation, Mexico, Poland, Ukraine, Israel, Puerto Rico
Cliniques universitaires Saint-Luc- Université...

Completed

Evaluation of Glycemic Changes During Exercise in Children With Type 1 Diabetes (TREAD-DIAB)

Type 1 Diabetes

Belgium
Eli Lilly and Company
Boehringer Ingelheim

Completed

A Study in Adults With Type 1 Diabetes (ELEMENT 1)

Diabetes Mellitus, Type 1

Japan, United States, Greece, Belgium, Poland, Germany, Hungary, Mexico, Romania
Population Health Research Institute
Hamilton Health Sciences Corporation

Completed

Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)

Type 2 Diabetes Mellitus

Canada
Eli Lilly and Company

Completed

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes (AUTONOMY)

Diabetes Mellitus, Type 2

United States, Puerto Rico, Poland, Canada, Austria, Mexico, Denmark, Croatia, Brazil, Argentina, Romania, South Africa, Russian Federation, France, Lithuania
Sanofi

Completed

Insulin Glargine in Type 2 Diabetes

Diabetes Mellitus, Type 2

Turkey
Sanofi

Completed

Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

France, Russian Federation, Croatia, Slovenia, Czech Republic, Romania
Sanofi

Completed

Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial) (AT-LANTUS)

Diabetes Mellitus, Type 1
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan (LIXILAN JP-O1)

Type 2 Diabetes Mellitus

Japan
Eli Lilly and Company

Completed

Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast

Diabetes Mellitus, Type 2

Canada, India, Romania, Spain, Mexico, Turkey, Portugal, Egypt
Riverside University Health System Medical Center

Terminated

Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting

Type 2 Diabetes Mellitus

United States
Emory University

Completed

A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus

Diabetes Mellitus | Type 1 Diabetes

United States
Eli Lilly and Company

Completed

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus

Type 1 Diabetes

China
Ohio University
Western University of Health Sciences

Completed

INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes (INSPIRE)

Type 2 Diabetes

United States
Assaf-Harofeh Medical Center

Terminated

Glucose Control With Multiple Daily Insulin Injections In Diabetic Patients Hospitalized In A General Medicine Ward

Diabetes Mellitus

Israel
Eli Lilly and Company

Completed

A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
Eli Lilly and Company

Completed

A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics

Type 1 Diabetes Mellitus

United States
Sanofi

Completed

PUMP STUDY MDI Lantus/Lispro vs Continuous Insulin+Lispro

Diabetes Mellitus
Sanofi

Completed

Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine (QoL)

Diabetes Type 2

Sweden
Eli Lilly and Company

Completed

A Study of LY3209590 in Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada
Hoffmann-La Roche

Terminated

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Diabetes Mellitus Type 2

China, Hong Kong, Korea, Republic of, Philippines, Taiwan, Malaysia, Thailand
Eli Lilly and Company

Completed

A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

China
Eli Lilly and Company

Completed

A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

Type 2 Diabetes

United States, Puerto Rico
Eli Lilly and Company

Completed

A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes

Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin (OPTIMIZATION)

Diabetes Mellitus, Type 2

China
Hoffmann-La Roche

Completed

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Diabetes Mellitus Type 2

Australia, Belgium, Hong Kong, United States, Germany, Portugal, Russian Federation, France, Canada, Finland, Austria, New Zealand, Spain, Poland, Thailand, Italy, Serbia, Korea, Republic of, Hungary, Mexico, Greece, Puerto Rico, Gu... and more
ikfe-CRO GmbH
IKFE Institute for Clinical Research and Development

Completed

Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin

Type 2 Diabetic Patients | Insufficient Metabolic Control | OAD Treatment

Germany

Search clinical trials for: Insulin glargine (LANTUS)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations